Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome.
IRCCS Neuromed, Pozzilli, Italy.
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):248-251. doi: 10.1093/ehjcvp/pvaa030.
Since December 2019, a new coronavirus, named SARS-CoV-2, has spread globally, affecting >200 000 people worldwide with the so-called COVID-19 disease. The scientific community is actively and constantly working to identify the mechanisms involved in the diffusion of this virus and the pathogenesis of the infection, with its most frequent and severe complication, namely interstitial pneumonia. To date, SARS-CoV-2 is known to enter the host cells via the angiotensin-converting enzyme 2 protein. For this reason, the hypothesis that drugs capable of increasing the expression of this protein may have a role in the spread of the virus and in the symptomatology of affected patients has taken hold. The purpose of this Editorial is to briefly show the evidence currently available in this regard and to provide ideas for future research.
自 2019 年 12 月以来，一种新型冠状病毒（SARS-CoV-2）在全球范围内传播，导致全球超过 20 万人感染所谓的 COVID-19 疾病。科学界正在积极和不断地努力识别这种病毒传播的机制和感染的发病机制，其最常见和最严重的并发症是间质性肺炎。迄今为止，已知 SARS-CoV-2 通过血管紧张素转换酶 2 蛋白进入宿主细胞。因此，关于能够增加这种蛋白表达的药物可能在病毒传播和受影响患者的症状学中起作用的假说已经得到认可。本社论的目的是简要展示这方面目前可用的证据，并为未来的研究提供思路。
